Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Wednesday, December 31, 2025 1 min read
Key Takeaway: AbbVie Inc. published its guidance for the quarter and full year ending December 31, 2025, highlighting the effects of acquired IPR D and milestones expense. For Q4 2025, the predicted adjusted diluted earnings per share (EPS) range is $2.61 to $2.65, accounting for a significant expense of approximately $1.265 billion. When excluding this expense, the guidance is higher, indicating a considerable adjustment to earnings expectations. Overall, while AbbVie anticipates growth, the additional costs present a financial challenge for the company's performance.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie provided detailed financial guidance for Q4 and full-year 2025.
The estimated adjusted diluted EPS remains in a competitive range.
The guidance reflects expected growth despite the additional expenses.
CONCERNS & RISKS
Acquired IPR D and milestones expenses will significantly impact earnings.
The projected adjusted EPS is lower when including the expense.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended December 31, 2025
Full-Year Ended December 31, 2025
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q4 2025 acquired IPR D and milestones expense
$
-
$
3.32
$
3.36
$
3,751
$
10.61
$
10.65
Q4 2025 acquired IPR D and milestones expense
1,265
(0.71)
(0.71)
1,265
(0.71)
(0.71)
Guidance including Q4 2025 Acquired IPR D and milestones expense
$
1,265
$
2.61
$
2.65
$
5,016
$
9.90
$
9.94
Frequently Asked Questions
What is the acquired IPR D expense for Q4 2025?
$1,265 million is the expense for acquired IPR D in Q4 2025.
What is the adjusted diluted EPS range for Q4 2025?
The adjusted diluted EPS range for Q4 2025 is $2.61 to $2.65.
How does the guidance change with Q4 2025 expenses?
With Q4 2025 expenses included, guidance shows $1,265 million and EPS of $2.61-$2.65.
What impact does the expense have on full-year 2025 EPS?
For full-year 2025, the guidance EPS range is $9.90 to $9.94 with these expenses.
What was the previously announced EPS range without Q4 2025 expenses?
The previous EPS range was $3.32 to $3.36, excluding Q4 2025 expenses.